000165756 001__ 165756 000165756 005__ 20260113234335.0 000165756 0248_ $$2sideral$$a147130 000165756 037__ $$aART-2019-147130 000165756 041__ $$aeng 000165756 100__ $$aLópez-Calleja, Ana Isabel 000165756 245__ $$aAntimicrobial activity of ceftolozane-tazobactam against multidrug-resistant and extensively ddrug-resistant pseudomonas aeruginosa clinical isolates from a spanish Hospital 000165756 260__ $$c2019 000165756 5060_ $$aAccess copy available to the general public$$fUnrestricted 000165756 5203_ $$aObjectives. Our objective was to evaluate the in vitro activity of ceftolozane-tazobactam against multidrugresistant (MDR) and extensively drug-resistant (XDR) non metallo-β-lactamase producing Pseudomonas aeruginosa clinical isolates at Hospital Universitario Miguel Servet (Zaragoza, Spain) from February 2016 to October 2017. Material and methods. We evaluated the in vitro activity of ceftolozane-tazobactam and other antipseudomonal antibiotics against 12 MDR and 117 XDR non metallo-β-lactamase producing P. aeruginosa isolates. Ceftolozane-tazobactam minimal inhibitory concentrations (MICs) were determined by MIC gradient diffusion test strip. Results. Among the 129 MDR/XDR isolates included, 119 (92.2%) were susceptible to ceftolozane-tazobactam, and ten (7.8%) were resistant. MIC50 was 2 mg/L, and MIC90 4 mg/L. Ceftolozane-tazobactam was the second most active antibiotic after colistin, overtaking amikacin. Conclusions. Ceftolozane-tazobactam is a valuable treatment option for MDR and XDR P. aeruginosa infections in our setting. 000165756 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc$$uhttps://creativecommons.org/licenses/by-nc/4.0/deed.es 000165756 590__ $$a1.132$$b2019 000165756 591__ $$aPHARMACOLOGY & PHARMACY$$b246 / 270 = 0.911$$c2019$$dQ4$$eT3 000165756 591__ $$aMICROBIOLOGY$$b121 / 133 = 0.91$$c2019$$dQ4$$eT3 000165756 592__ $$a0.287$$b2019 000165756 593__ $$aMedicine (miscellaneous)$$c2019$$dQ3 000165756 593__ $$aPharmacology$$c2019$$dQ3 000165756 593__ $$aMicrobiology (medical)$$c2019$$dQ3 000165756 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion 000165756 700__ $$aMorilla, Elena 000165756 700__ $$aNuñez, Rossi 000165756 700__ $$aFernández Esgueva, Marta 000165756 700__ $$aSahagún, Juan$$uUniversidad de Zaragoza 000165756 700__ $$0(orcid)0000-0002-9582-5472$$aGarcía-Lechuz, Juan Manuel 000165756 700__ $$aFerrer Cerón, Isabel 000165756 700__ $$0(orcid)0000-0003-2044-6782$$aViñuelas, Jesús$$uUniversidad de Zaragoza 000165756 700__ $$0(orcid)0000-0001-7294-245X$$aRezusta, Antonio$$uUniversidad de Zaragoza 000165756 7102_ $$11008$$2630$$aUniversidad de Zaragoza$$bDpto. Microb.Med.Pr.,Sal.Públ.$$cÁrea Microbiología 000165756 773__ $$g32, 1 (2019), 68-72$$pRev. esp. quimioter.$$tRevista española de quimioterapia$$x0214-3429 000165756 8564_ $$s185381$$uhttps://zaguan.unizar.es/record/165756/files/texto_completo.pdf$$yVersión publicada 000165756 8564_ $$s2184907$$uhttps://zaguan.unizar.es/record/165756/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada 000165756 909CO $$ooai:zaguan.unizar.es:165756$$particulos$$pdriver 000165756 951__ $$a2026-01-13-22:07:41 000165756 980__ $$aARTICLE